Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Poseida Therapeutics stock

Own Poseida Therapeutics stock in just a few minutes.


Fact checked

Poseida Therapeutics, Inc is a biotechnology business based in the US. Poseida Therapeutics shares (PSTX) are listed on the NASDAQ and all prices are listed in US Dollars. Poseida Therapeutics employs 186 staff and has a market cap (total outstanding shares value) of USD$627.5 million.

How to buy shares in Poseida Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Poseida Therapeutics. Find the stock by name or ticker symbol: PSTX. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Poseida Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Poseida Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Poseida Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Poseida Therapeutics share price

Use our graph to track the performance of PSTX stocks over time.

Poseida Therapeutics shares at a glance

Information last updated 2021-02-24.
52-week rangeUSD$7.63 - USD$17.62
50-day moving average USD$9.4452
200-day moving average USD$10.077
Wall St. target priceUSD$25
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) N/A

Buy Poseida Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Gold/Commodities
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, Options, Cryptocurrency
Stocks & ETFs: $1/contract to open, $0 to close, $10 max/leg
Futures: $2.50/contract to open, $0 to close
Get 100 shares of stock (worth $1 to $6 a share)
Open and fund a new cash or margin account with $2,000+
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
$0 for US stocks
Stocks, Options, ETFs
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Poseida Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Poseida Therapeutics financials

Gross profit TTM USD$0
Return on assets TTM 0%
Return on equity TTM 0%
Profit margin 0%
Book value N/A
Market capitalisation USD$627.5 million

TTM: trailing 12 months

Shorting Poseida Therapeutics shares

There are currently 1.9 million Poseida Therapeutics shares held short by investors – that's known as Poseida Therapeutics's "short interest". This figure is 14.6% up from 1.6 million last month.

There are a few different ways that this level of interest in shorting Poseida Therapeutics shares can be evaluated.

Poseida Therapeutics's "short interest ratio" (SIR)

Poseida Therapeutics's "short interest ratio" (SIR) is the quantity of Poseida Therapeutics shares currently shorted divided by the average quantity of Poseida Therapeutics shares traded daily (recently around 298954.31309904). Poseida Therapeutics's SIR currently stands at 6.26. In other words for every 100,000 Poseida Therapeutics shares traded daily on the market, roughly 6260 shares are currently held short.

However Poseida Therapeutics's short interest can also be evaluated against the total number of Poseida Therapeutics shares, or, against the total number of tradable Poseida Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Poseida Therapeutics's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Poseida Therapeutics shares in existence, roughly 30 shares are currently held short) or 0.0608% of the tradable shares (for every 100,000 tradable Poseida Therapeutics shares, roughly 61 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Poseida Therapeutics.

Find out more about how you can short Poseida Therapeutics stock.

Poseida Therapeutics share dividends

We're not expecting Poseida Therapeutics to pay a dividend over the next 12 months.

Poseida Therapeutics overview

Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company is developing a pipeline of solutions for the treatment of hematological malignancies and solid tumors, as well as vivo programs for liver-directed gene therapies for rare diseases. In addition, it offers CAR-T therapies for the treatment for cancer. Further, it offers gene therapies for rare and life-threatening diseases, including Ornithine transcarbamylase (OTC) deficiency and methylmalonic acidemia (MMA), and genetic liver diseases. The company was founded in 2014 and is headquartered in San Diego, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site